Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Artigo
|
![]() |
Avascular necrosis of the jaws: risk factors in metastatic cancer patientsTarassoff, Peter ; Csermak, KatalinJournal of oral and maxillofacial surgery, 2003-10, Vol.61 (10), p.1238-1239 [Periódico revisado por pares]United States: Elsevier IncTexto completo disponível |
2 |
Material Type: Artigo
|
![]() |
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancerRothenberg, M. L. ; Moore, M. J. ; Cripps, M. C. ; Andersen, J. S. ; Portenoy, R. K. ; Burriss, H. A. ; Green, M. R. ; Tarassoff, P. G. ; Brown, T. D. ; Casper, E. S. ; Storniolo, A.-M. ; Von Hoff, D. D.Annals of oncology, 1996-04, Vol.7 (4), p.347-353 [Periódico revisado por pares]Oxford: Oxford University PressTexto completo disponível |
3 |
Material Type: Artigo
|
![]() |
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trialBURRIS, H. A ; MOORE, M. J ; NELSON, R ; DORR, F. A ; STEPHENS, C. D ; VON HOFF, D. D ; ANDERSEN, J ; GREEN, M. R ; ROTHENBERG, M. L ; MODIANO, M. R ; CRIPPS, M. C ; PORTENOY, R. K ; STORNIOLO, A. M ; TARASSOFF, PJournal of clinical oncology, 1997-06, Vol.15 (6), p.2403-2413 [Periódico revisado por pares]Baltimore, MD: American Society of Clinical OncologySem texto completo |
4 |
Material Type: Artigo
|
![]() |
Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreasCASPER, E. S ; GREEN, M. R ; KELSEN, D. P ; HEELAN, R. T ; BROWN, T. D ; FLOMBAUM, C. D ; TROCHANOWSKI, B ; TARASSOFF, P. GInvestigational new drugs, 1994-01, Vol.12 (1), p.29-34 [Periódico revisado por pares]Dordrecht: KluwerTexto completo disponível |
5 |
Material Type: Artigo
|
![]() |
Improvements in Survival and Clinical Benefit With Gemcitabine as First-Line Therapy for Patients With Advanced Pancreas Cancer: A Randomized TrialBurris, 3rd, H A ; Moore, M J ; Andersen, J ; Green, M R ; Rothenberg, M L ; Modiano, M R ; Cripps, M C ; Portenoy, R K ; Storniolo, A M ; Tarassoff, P ; Nelson, R ; Dorr, F A ; Stephens, C D ; Von Hoff, D DJournal of clinical oncology, 2023-12, Vol.41 (36), p.5482-5492 [Periódico revisado por pares]United StatesSem texto completo |
6 |
Material Type: Artigo
|
![]() |
Osteonecrosis of the Jaw and BisphosphonatesDurie, Brian G M ; Katz, Michael ; Crowley, JohnThe New England journal of medicine, 2005-07, Vol.353 (1), p.99-102 [Periódico revisado por pares]United States: Massachusetts Medical SocietyTexto completo disponível |
7 |
Material Type: Artigo
|
![]() |
A phase I clinical, plasma, and cellular pharmacology study of gemcitabineAbbruzzese, J L ; Grunewald, R ; Weeks, E A ; Gravel, D ; Adams, T ; Nowak, B ; Mineishi, S ; Tarassoff, P ; Satterlee, W ; Raber, M NJournal of clinical oncology, 1991-03, Vol.9 (3), p.491-498 [Periódico revisado por pares]United States: American Society of Clinical OncologySem texto completo |
8 |
Material Type: Artigo
|
![]() |
Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancerFOSSELLA, F. V ; LIPPMAN, S. M ; WAUN KI HONG ; SHIN, D. M ; TARASSOFF, P ; CALAYAG-JUNG, M ; PEREZ-SOLER, R ; JIN SOO LEE ; MURPHY, W. K ; GLISSON, B ; RIVERA, EJournal of clinical oncology, 1997-01, Vol.15 (1), p.310-316 [Periódico revisado por pares]Baltimore, MD: American Society of Clinical OncologySem texto completo |
9 |
Material Type: Artigo
|
![]() |
Therapeutic Vaccines for Prostate CancerTarassoff, Christopher P. ; Arlen, Philip M. ; Gulley, James L.The oncologist (Dayton, Ohio), 2006-05, Vol.11 (5), p.451-462 [Periódico revisado por pares]Durham, NC, USA: AlphaMed PressTexto completo disponível |
10 |
Material Type: Artigo
|
![]() |
Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology studyGRUNEWALD, R ; KANTARJIAN, H ; DU, M ; FAUCHER, K ; TARASSOFF, P ; PLUNKETT, WJournal of clinical oncology, 1992-03, Vol.10 (3), p.406-413 [Periódico revisado por pares]PHILADELPHIA: American Society of Clinical OncologySem texto completo |